These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35361613)

  • 21. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.
    McIntyre P; Amin J; Gidding H; Hull B; Torvaldsen S; Tucker A; Turnbull F; Burgess M
    Commun Dis Intell; 2000 Jun; Suppl():v-83. PubMed ID: 12049363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
    Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
    BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measles, mumps, and rubella: monitoring in Switzerland through a sentinel network, 1986-94. Sentinella Arbeitsgemeinschaft.
    Matter HC; Cloetta J; Zimmermann H
    J Epidemiol Community Health; 1995 Aug; 49 Suppl 1(Suppl 1):4-8. PubMed ID: 7561669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Representativeness, Vaccination Uptake, and COVID-19 Clinical Outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: Cohort Profile Summary.
    Leston M; Elson WH; Watson C; Lakhani A; Aspden C; Bankhead CR; Borrow R; Button E; Byford R; Elliot AJ; Fan X; Hoang U; Linley E; Macartney J; Nicholson BD; Okusi C; Ramsay M; Smith G; Smith S; Thomas M; Todkill D; Tsang RS; Victor W; Williams AJ; Williams J; Zambon M; Howsam G; Amirthalingam G; Lopez-Bernal J; Hobbs FDR; de Lusignan S
    JMIR Public Health Surveill; 2022 Dec; 8(12):e39141. PubMed ID: 36534462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the COVID-19 pandemic on vaccine coverage for early childhood vaccines in Alberta, Canada: a population-based retrospective cohort study.
    MacDonald SE; Paudel YR; Kiely M; Rafferty E; Sadarangani M; Robinson JL; Driedger SM; Svenson LW;
    BMJ Open; 2022 Jan; 12(1):e055968. PubMed ID: 35078849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
    Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
    PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions.
    Schäfer W; Reinders T; Schink T
    Vaccine; 2022 Mar; 40(14):2168-2172. PubMed ID: 35232594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
    Alfredsson R; Svensson E; Trollfors B; Borres MP
    Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measles, mumps, rubella prevention: how can we do better?
    Kauffmann F; Heffernan C; Meurice F; Ota MOC; Vetter V; Casabona G
    Expert Rev Vaccines; 2021 Jul; 20(7):811-826. PubMed ID: 34096442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. National and state vaccination coverage among children aged 19-35 months--United States, 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Sep; 60(34):1157-63. PubMed ID: 21881546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the COVID-19 pandemic on routine childhood immunisation in Colombia.
    Moreno-Montoya J; Ballesteros SM; Rojas Sotelo JC; Bocanegra Cervera CL; Barrera-López P; De la Hoz-Valle JA
    Arch Dis Child; 2022 Mar; 107(3):e4. PubMed ID: 34285000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increasing childhood vaccination coverage of the refugee and migrant population in Greece through the European programme PHILOS, April 2017 to April 2018.
    Mellou K; Silvestros C; Saranti-Papasaranti E; Koustenis A; Pavlopoulou ID; Georgakopoulou T; Botsi C; Terzidis A
    Euro Surveill; 2019 Jul; 24(27):. PubMed ID: 31290391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.
    Vesikari T; Karvonen A; Lindblad N; Korhonen T; Lommel P; Willems P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2010 Jun; 29(6):e47-56. PubMed ID: 20508478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten - United States, 2020-21 School Year.
    Seither R; Laury J; Mugerwa-Kasujja A; Knighton CL; Black CL
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(16):561-568. PubMed ID: 35446828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients.
    Gold JE; Baumgartl WH; Okyay RA; Licht WE; Fidel PL; Noverr MC; Tilley LP; Hurley DJ; Rada B; Ashford JW
    mBio; 2020 Nov; 11(6):. PubMed ID: 33219096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination Coverage Among Children Aged 2 Years - U.S. Affiliated Pacific Islands, April-October, 2016.
    Tippins A; Murthy N; Meghani M; Solsman A; Apaisam C; Basilius M; Eckert M; Judicpa P; Masunu Y; Pistotnik K; Pedro D; Sasamoto J; Underwood JM
    MMWR Morb Mortal Wkly Rep; 2018 May; 67(20):579-584. PubMed ID: 29795077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seroconversion rates following 2 doses of measles- mumps- rubella vaccination given at the ages 12 and 18 months: data for possible additional dose at older age.
    Saffar H; Mousavi SJ; Saffar H; Parsaei MR; Ghorbani GR; Saffar MJ
    BMC Immunol; 2022 Jan; 23(1):2. PubMed ID: 35034609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study.
    La Torre G; Saulle R; Unim B; Meggiolaro A; Barbato A; Mannocci A; Spadea A
    Hum Vaccin Immunother; 2017 Aug; 13(8):1879-1883. PubMed ID: 28604255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.